![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioprogress | LSE:BPRG | London | Ordinary Share | GB0032681628 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:9652A BioProgress PLC 27 July 2007 For Immediate Release 27 July 2007 BioProgress plc ('BioProgress' or the 'Company') MenoflavonTM Product Update London, UK, 27 July 2007: BioProgress plc (AIM: BPRG), the speciality pharma and healthcare company, has today announced that Melbrosin will be sponsoring lectures at the First International Congress of Breast Development, Functions and Diseases in Turin, Italy on 28-30 September 2007 and promoting MenoflavonTM, its natural product for menopausal symptoms, to 800 delegates. The MenoflavonTM brand will also be launched in France to coincide with the Congress. The lectures that highlight the use of MenoflavonTM will be given by two leading key opinion leaders in the field of female health, Professor Martin Imhof from the Medical University of Vienna, Austria and Dr Tommaso Simoncini from the University of Pisa, Italy. The lectures will be part of a session on Red clover isoflavones and breast. Prof. M. Imhof will present a lecture on "The impact of isoflavones on breast" and Dr. T. Simoncini will discuss "Estrogens, phytoestrogens and the postmenopausal woman: impact on the cardiovascular system and on the breast". Isoflavones derived from red clover, the main constituent of MenoflavonTM, in addition to being an alternative to hormone replacement therapy, potentially have beneficial cardiovascular actions, along with estrogen antagonistic actions on breast cancer cells which will be discussed in this lecture, along with the implications for the care of postmenopausal women. MenoflavonTM is a strategic growth product of Melbrosin and is currently being marketed in Germany, Austria and Italy. Since its launch in 2001, MenoflavonTM has sold over 2.5 million units and is one of the leading red clover products worldwide. It is currently available in 20 markets and it is anticipated to launch in H2 2007 into six additional South American countries. The product sales are currently growing at 14-30% per annum. The non-prescription menopausal product market is estimated to be in excess of Euro200m in the top six countries in Europe, with Germany accounting for Euro75m, France Euro57m and Italy Euro23m. From the cash raised at the time of the Melbrosin acquisition, MenoflavonTM will be launched in France to coincide with the presentations. It is anticipated that the range of products available will be extended by utilising BioProgress' X-Gel technology. It is expected that other territory launches will occur throughout the remainder of 2007. Richard Trevillion, Chief Executive Officer, BioProgress, said: "This is an important step in our development as a speciality pharmaceutical company. This launch demonstrates the fast organic growth of our core brands. With the rollout of the brand to multiple territories over the coming months, we are pleased that our integration strategy is on track and poised for strong growth." Steve Martin, Chief Development Officer, BioProgress, said: "BioProgress is pleased that we are able to promote MenoflavonTM to the established medical and pharmaceutical industries. The potential benefits of MenoflavonTM are only just being understood and with potentially wider benefits against the traditional hormone replacement market, MenoflavonTM is able to offer real choice in alternative therapy. The use of such international meetings is a core strategy of the business going forward as it seeks to expand, and validate, the uses and indications of products and technologies that have been acquired or are under development. " Klaus Kuhne, Joint Managing Director, Melbrosin, said: "We have a strong science behind our core brands, with MenoflavonTM being no exception. The superior nature of the product compared to its peers has allowed the brand to enjoy healthy growth potential. We have two internationally recognised key opinion leaders who have conducted research into MenoflavonTM. We are excited that we are able to expand our promotional efforts and increase the distribution as a direct result of working with and being part of BioProgress." For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGELTM polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com Forward-Looking Information. The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. This information is provided by RNS The company news service from the London Stock Exchange END MSCRFMRTMMJTBTR
1 Year Bioprogress Chart |
1 Month Bioprogress Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions